Helix BioPharmaHBPCF 28 Current Ratio is 0.45 as of Apr. 2026, which is 42% below its 10-year median of 0.77. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,417 Biotechnology companies, Helix BioPharma ranks worse than 91.67% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Helix BioPharma's current ratio for the quarter that ended in Apr. 2026 was 0.45.
Helix BioPharma has a current ratio of 0.45. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Helix BioPharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Helix BioPharma's Current Ratio or its related term are showing as below:
HBPCF'
s Current Ratio Range Over the Past 10 Years
Min: 0.04 Med: 0.77 Max: 3.95
Current: 0.45
During the past 13 years, Helix BioPharma's highest Current Ratio was 3.95. The lowest was 0.04. And the median was 0.77.
HBPCF's Current Ratio is ranked worse than 91.67% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs HBPCF: 0.45
Helix BioPharma (OTCPK:HBPCF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Helix BioPharma Current Ratio Related Terms
Helix BioPharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBPCF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Helix BioPharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a Current Ratio of 0.45 as of Apr. 2026. This is 42% below median its historical median of 0.77. Over the past decade, Helix BioPharma's Current Ratio has ranged from 0.04 to 3.95. According to the industry distribution chart, Helix BioPharma ranks #1299 out of 1417 companies in the Biotechnology industry, placing it in the top 91.7%.
Is Helix BioPharma's Current Ratio too high?
Helix BioPharma's current Current Ratio of 0.45 is 42% below median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 3.95. The Biotechnology industry median Current Ratio is 3.89. Helix BioPharma's value of 0.45 is 88.4% below this industry median. Based on the distribution chart, Helix BioPharma ranks #1299 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #1299 out of 1417 companies for Current Ratio. This places Helix BioPharma in the lower half of its industry. The industry median Current Ratio is 3.89. Helix BioPharma's value of 0.45 is 88.4% below this benchmark. Historically, Helix BioPharma's own Current Ratio has ranged from 0.04 to 3.95 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 3.89, Helix BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helix BioPharma's current Current Ratio of 0.45 is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current Current Ratio is 0.45, which is 42% below median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Current Ratio of 0.45. The current Current Ratio is 0.45, which is 42% below median its 10-year median of 0.77 and 88.4% below the Biotechnology industry median of 3.89. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Current Ratio is 0.45 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
